Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations by Reuman, Elizabeth C. et al.
Constrained patterns of covariation and clustering of HIV-1
non-nucleoside reverse transcriptase inhibitor resistance mutations
Elizabeth C.Reuman1*, Soo-Yon Rhee1, Susan P. Holmes2 and Robert W. Shafer1
1Division of Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Grant S-146, Stanford, CA 9305, USA;
2Department of Statistics, Stanford University, Sequoia Hall, 390 Serra Mall, Stanford, CA 94305, USA
*Corresponding author. Tel: +1-650-723-2642; Fax: +1-650-725-2395; E-mail: ereuman@stanford.edu
Received 9 February 2010; returned 7 March 2010; revised 30 March 2010; accepted 1 April 2010
Objectives: We characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibi-
tor (NNRTI)-selected mutations because multiple mutations are usually required for clinically signiﬁcant resist-
ance to second-generation NNRTIs.
Patients and methods: We analysed viruses from 13039 individuals with sequences containing at least one of
52 published NNRTI-selected mutations, including 1133 viruses from individuals who received efavirenz but no
other NNRTI and 1510 viruses from individuals who received nevirapine but no other NNRTI. Of the 17 reported
etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major
based on published in vitro susceptibility data.
Results: Efavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P,0.001), K101P
(3.3% versus 0.4%, P,0.001) and M230L (2.8% versus 1.3%, P¼0.004), whereas nevirapine preferentially
selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P,0.001). Twenty-nine pairs of NNRTI-
selected mutations covaried signiﬁcantly, including Y181C with seven other mutations (A98G, K101E/H,
V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S. Two pairs (Y181C+V179F and
Y181C+G190S) were predicted to confer .10-fold decreased etravirine susceptibility. Seventeen percent of
sequences had three or more NNRTI-selected mutations, mostly in clusters of covarying mutations. Many clus-
ters had Y181C plus a non-major etravirine RAM; few had more than one major etravirine RAM.
Conclusions: Although major etravirine RAMs rarely occur in combination, 2 of 29 pairs of covarying mutations
were associated with .10-fold decreased etravirine susceptibility. Viruses with three or more NNRTI-selected
mutations often contained Y181C in combination with one or more minor etravirine RAMs; however, phenotypic
and clinical correlates for most of these higher order combinations have not been published.
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Introduction
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind
to a hydrophobic pocket in the reverse transcriptase (RT) enzyme
close to, but not contiguous with, the polymerase active site.
These compounds inhibit HIV-1 replication allosterically by block-
ing translocation of the template–primer following nucleotide
incorporation, or by displacing the catalytic aspartate residues
relative to the polymerase-binding site. Mutations responsible
for NNRTI resistance occur in this hydrophobic inhibitor-binding
pocket.
1 A single mutation in this pocket can lead to high-level
resistance to one or more ﬁrst-generation NNRTIs, including efa-
virenz and nevirapine. However, two or more mutations are
required to cause high-level resistance to etravirine, rilpivirine
and other second-generation NNRTIs.
2–5 Therefore, we decided
to explore the landscape of NNRTI resistance mutations in com-
binations of two or more, as viruses with these combinations are
likely to be most troublesome for NNRTIs with higher genetic bar-
riers to resistance.
We used publicly available HIV-1 RT sequence data from the
HIV Drug Resistance Database (HIVDB)
6 to identify patterns of
mutations associated with efavirenz and nevirapine, the two
most commonly used ﬁrst-generation NNRTIs, and examined
pairwise and higher order correlations among NNRTI-selected
mutations. Our results provide new insights into the genetic
mechanisms of NNRTI resistance and have important impli-
cations for the use of second-generation NNRTIs.
# The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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1477Patients and methods
Virus RT sequences
HIV-1 Group M RTsequences were compiled from published studies in the
HIVDB. These included a set of 47350 sequences from 39687 individuals
and a set of 9349 sequences from a large reference laboratory.
7 To use
no more than a single sequence per individual, we selected the sequence
with the greatest number of NNRTI-selected mutations from each of the
individuals in the ﬁrst set and excluded all those (n¼2548) from the
second set that differed from each other at ,5.0% of their nucleotide
positions.
We studied only sequences obtained by direct PCR sequencing of
plasma HIV-1 RNA because these are the sequences obtained in clinical
settings. Sequences of molecular clones were excluded because of their
higher probability of containing PCR errors.
8 Sequences obtained from
other sources, particularly proviral peripheral blood mononuclear cell
DNA, were excluded because they are at higher risk of containing defec-
tive genomes such as viruses with G to A hypermutation.
9,10
To assess the patterns in which NNRTI-selected mutations occur, we
analysed only those sequences containing one or more NNRTI-selected
mutations. This enabled us to study sequences obtained from individuals
who are likely to be NNRTI experienced, regardless of the availability of a
complete treatment history or the possibility of non-adherence.
We analysed 52 NNRTI-selected mutations at 30 positions. These
mutations included: (i) 46 non-polymorphic NNRTI-selected mutations
at 28 positions (I94L, A98G, L100I, K101E/H/N/P, K102N, K103H/N/S/T,
S105T, V106A/M, E138Q, T139R, I178F, V179F, Y181C/I/V, Y188C/H/L,
G190A/C/E/Q/S, H221C/Y, K223T, P225H, F227L/Y, M230L, Y232H, L234I,
P236L, D237E, K238N/T, V241M, Q242L and Y318F);
11 and (ii) several
polymorphic mutations that have been associated with decreased
susceptibility to one or more NNRTIs (V108I) or are included in the etra-
virine resistance-associated mutations (RAMs) (V90I, V106I, E138A and
V179D/T).
4
The complete list of etravirine RAMs was deﬁned as V90I, A98G,
L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and
M230L.
4 Of these, L100I, K101P, Y181C/I/V and M230L were considered
to be major etravirine RAMs based on their marked effect on etravirine
susceptibility.
4,12–14
Comparison of nevirapine- and efavirenz-selected
mutations
We characterized each NNRTI-selected mutation by its frequency within
sequences from individuals with a history of having received either
efavirenz but no other NNRTI, or nevirapine but no other NNRTI.
We then calculated the Pearson x
2 statistic for the association of each
NNRTI-selected mutation with efavirenz or nevirapine treatment, based
on a 2×2 contingency table of the numbers of isolates from patients
treated with each drug and the numbers of isolates with and without
the mutation. For this analysis only, electrophoretic mixtures were
scored as mutations.
Covariation analysis
We used the Jaccard similarity coefﬁcient (J) to identify pairwise corre-
lations among the 52 NNRTI mutations in 13039 sequences from
unique individuals. Covariation analysis was run on the full set of
sequences and on the subsets corresponding to sequences from individ-
uals with a history of receiving either efavirenz or nevirapine but no other
NNRTI.
We created 2×2 contingency tables to indicate the number of times a
sequence contained both mutations, only one of the two mutations or
neither of the two mutations. Overall, there were 1288 contingency
tables representing all possible pairs of mutations except for permu-
tations of mutation pairs at the same position: 1326 (52 choose 2)
pairs minus 38 pairs of mutations at the same position. For each com-
parison, sequences containing an electrophoretic mixture at either of
the two positions were excluded because of the inability to determine
whether the two NNRTI-selected mutations were present in the same
genome.
For a pair of mutations X and Y, the Jaccard similarity coefﬁcient is cal-
culated as J¼NXY/(NXY+NX0+N0Y) where NXY represents the number of
sequences containing mutation X and mutation Y, NX0 represents the
number of sequences containing X but not Y, and N0Y represents the
sequences containing Y but not X. This statistic therefore examines only
the sequences containing both X and Y in the context of sequences con-
taining at least one of the mutations, thereby eliminating the heavy
weighting given to the double-negative category in such statistical ana-
lyses as the x
2 test. This is particularly important so as not to exaggerate
the signiﬁcance of pairs of rare mutations, where the double-negative
category is very large.
15
To test whether the observed Jaccard similarity coefﬁcients were stat-
istically signiﬁcant, we calculated the expected value of the Jaccard simi-
larity coefﬁcient (JRAND) for each pair of mutations as if the two
mutations (X and Y) occurred independently. JRAND was calculated as
the mean Jaccard similarity coefﬁcient after 2000 random rearrange-
ments of the X or Y vector (containing 0 or 1 for the presence or
absence of a mutation, respectively). JSE, the standard error of J, was cal-
culated using a jackknifed procedure, which removed one sequence at a
time, repeatedly for each sequence.
15 The standardized score Z, where
Z¼(J2JRAND)/JSE, indicates a signiﬁcant positive association when
Z.1.96 or a signiﬁcant negative association when Z is less than
21.96, at an unadjusted P,0.05. The case of NXY¼0 results in a
Z-score of negative inﬁnity; Fisher’s exact one-tailed test, using the
R command ﬁsher.test with a left-tailed alternative hypothesis, was
used to approximate the P value for those comparisons with NXY¼0.
Holm’s correction was used to control the familywise error rate for
multiple pairwise comparisons.
16 The P values of the n pairwise compari-
sons are ranked in ascending order, where p(1) is the smallest (ranked
ﬁrst) and p(i) is the ith ranked. Starting from p(1), one compares each
p(i) with p/(n2i+1) where p is the false discovery rate (in this
case, 0.05) and n is the total number of pairwise comparisons, until
p(j).p/(n2j+1). All correlations between pairs for p(1),..., p(j21) are
considered statistically signiﬁcant.
We modelled the distributions of mutations in each sequence using
Poissonness plots, following the method of Hoaglin,
17 and conducted a
parametric bootstrap using a multivariate Poisson simulation to assess
the distribution of positive and negative correlations obtained from the
Jaccard covariation analysis. This step was important in evaluating the
possible biological signiﬁcance of the negative correlations.
We also examined the extent to which the 52 NNRTI-selected
mutations covaried with mutations at 12 major nucleoside reverse tran-
scriptase inhibitor (NRTI) resistance positions, including M41L, K65R,
D67N, T69S_SS, K70E, K70R, L74V, L74I, V75M/T, Y115F, Q151M,
M184V/I, L210W, T215F and T215Y.
18 Sequences that contained at
least one NNRTI-selected mutation and at least one of the above NRTI-
selected mutations were analysed using the same methods described
for assessing covariation within the NNRTI mutation dataset.
Multidimensional scaling
We performed multidimensional scaling on the pairwise association data
using a matrix D of dissimilarity coefﬁcients (JD¼12J, where J is the
Jaccard similarity coefﬁcient) for the 22 mutations found in the signiﬁ-
cantly positively associated pairs (corrected P,0.05): A98G, L100I,
K101E, K101H, K101P, K102N, K103N, K103S, V106A, V106I, V106M,
V108I, V179D, V179F, Y181C, Y188L, G190A, G190S, H221Y, P225H,
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scaling constructs points in two-dimensional (2-D) space such that the
Euclidean distances between these points approximate the entries in
the dissimilarity matrix.
19 For a given matrix, it computes points X1,
X2,..., Xn in 2-D space such that S¼Si,j(dist
2(Xi,Xj)2dij
2) is minimized
where dist(Xi,Xj) is the Euclidean distance between Xi and Xj, and dij is
the dissimilarity between Xi and Xj in the matrix D. This was performed
using the R function cmdscale (classical multidimensional scaling).
Cluster analysis
We also identiﬁed all sequences containing three or more NNRTI-selected
mutations and characterized the patterns of mutations by their fre-
quency in the dataset and by whether they were composed of mutations
that covaried with one another. Sets of three or more mutations in which
each mutation covaried with each of the other members in the set were
referred to as clusters or cliques (a term derived from graph theory).
A lower threshold for covariation was used for this analysis (uncorrected
P,0.05) than in the pairwise comparison, to facilitate the identiﬁcation
of clusters. As for all previous covariation analyses, we used no more
than one sequence per patient.
Results
Viruses and sequences
HIV-1 Group M RT sequences from 13039 individuals had ≥1o f
the 52 study-deﬁned NNRTI-selected mutations. Of these indi-
viduals, 2394 were NNRTI naive, 5699 were NNRTI experienced
and 4946 had uncertain NNRTI treatment histories. Among the
NNRTI-experienced individuals, 1133 had received efavirenz
only; 2292 had received nevirapine only (1510 who were
treated with nevirapine and 782 women who received a single
dose of nevirapine to prevent mother-to-child transmission);
and 430 had received both efavirenz and nevirapine. The com-
plete NNRTI treatment history was unavailable for the remaining
1844 NNRTI-experienced individuals. The dataset contained
6977 sequences (54% of the total) with one mutation, 3829
(29%) with two, 1521 (12%) with three, 501 (4%) with four,
172 (1%) with ﬁve, 36 (0.3%) with six, 2 with seven, and 1
with eight mutations. Sequences from 10504 individuals (81%)
belonged to subtype B, 747 (6%) to subtype C, 363 (3%) to cir-
culating recombinant form (CRF) 01_AE, 320 (2%) to CRF
02_AG, 210 (2%) to subtype A and 895 (7%) to other subtypes
or recombinants.
Comparison of efavirenz- and nevirapine-selected
mutations
Figure 1 compares the prevalence of each of the 52 NNRTI-
selected mutations in the sequences from the 1133 individuals
who received efavirenz only and from the 1510 individuals who
received nevirapine only. The most common mutations in
sequences from efavirenz-experienced individuals were K103N
(72% of the sequences), L100I (14%), P225H (11%), V108I
(11%), G190A (9.5%), Y188L (9.3%), G190S (7.2%), K101E
(7.2%) and V106M (7.0%). The most common mutations in
sequences from nevirapine-experienced individuals were Y181C
(46% of the sequences), K103N (43%), G190A (26%), H221Y
(12%) and K101E (11%). Twenty-eight mutations deviated sig-
niﬁcantly (P,0.05) from the distribution that would be expected
in the absence of treatment association. Figure 1a shows the 16
mutations that occurred signiﬁcantly more commonly in
efavirenz-exposed individuals (L100I, K101P, K103N, V106I/M,
V108I, V179D, Y188H/L, G190E/S/Q, P225H, F227Y, M230L and
K238T), and Figure 1b shows the 12 that occurred signiﬁcantly
more commonly in nevirapine-exposed individuals (A98G,
K101E, K103S, V106A, E138A, T139R, Y181C/I/V, Y188C, G190A
and H221Y). Figure 1c shows the frequencies of the mutations
that were not signiﬁcantly associated with either drug.
Among the sequences from 782 women treated with a single
dose of nevirapine, the most frequently observed mutations were
K103N (28%), Y181C (15%), Y188C (6%), G190A (5%) and E138A
(4%). Y188C was the only mutation to occur signiﬁcantly more
frequently among the single-dose nevirapine sequences (6%)
than among the full dataset of 1510 nevirapine-experienced
individuals (2%).
Sequences from 213 individuals (27%) had at least one etra-
virine RAM, including 118 (15%) with at least one major etravir-
ine RAM (115 with Y181C, 1 with L100I and 1 with both). No
sequence contained .3 etravirine RAMs.
Covariation of NNRTI-selected mutations
To examine the extent of covariation among the NNRTI-selected
mutations, we performed separate Jaccard analyses of the com-
plete set of sequences from 13039 individuals with viruses con-
taining at least one NNRTI-selected mutation, the 1133
sequences from individuals who had received only efavirenz
and the 1510 sequences from individuals who had received
only nevirapine. Among the 13039 sequences that comprised
the full dataset, 66 of the 1288 possible mutation pairs had posi-
tive covariances, and 29 of these covariances were statistically
signiﬁcant after the Holm’s adjustment for multiple comparisons
(P,0.05). Table 1 shows the results of this analysis on the 29
pairs of signiﬁcantly covarying mutations. G190A (n¼9), Y181C
(n¼8), V108I (n¼6), K101E (n¼4), H221Y (n¼4) and F227L
(n¼4) were the most common mutations among these 29
pairs. Tables S1 to S4 [available as Supplementary data at JAC
Online (http://jac.oxfordjournals.org/)] show the results of the
analysis on all 1288 mutation pairs for the complete dataset,
the efavirenz-alone dataset and the nevirapine-alone dataset.
Of the 29 pairs of mutations that were signiﬁcantly correlated
in the full dataset, 8 pairs covaried (uncorrected P,0.05) in the
efavirenz-alone subset, 5 pairs covaried in the nevirapine-alone
subset and 4 pairs covaried in both subsets (Table 1). In 13 of
the 29 signiﬁcantly covarying pairs, both mutations were prefer-
entially selected by the same NNRTI.
The major etravirine RAM Y181C was signiﬁcantly associated
with G190A, H221Y, V108I, A98G, G190S and V179F. L100I
was signiﬁcantly associated with K103N, and K101P was signiﬁ-
cantly associated with K103S. M230L was most strongly associ-
ated with K103N (P¼0.003 uncorrected, not signiﬁcant following
correction for multiple comparisons).
We also found 225 negatively correlated mutation pairs,
including 116 that had statistically signiﬁcant negative corre-
lations after adjusting for multiple comparisons. However, a
parametric bootstrap using the multivariate Poisson analysis of
a random dataset containing the same number of mutations
per sample and the same prevalence of each mutation indicates
that a large number of negative correlations is to be expected
Constrained NNRTI mutational patterns
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JACbecause our analysis included only isolates containing at least
one NNRTI resistance mutation.
Multidimensional scaling
We used the 22 mutations that contribute to ≥1 of the 29 signiﬁ-
cantly covarying pairs in the full dataset for multidimensional
scaling. Figure 2a, b and c shows the mutations on axes represent-
ingtheﬁrstversussecond,ﬁrstversusthirdandsecondversusthird
principal coordinates. The ﬁrst principal coordinate accounts for
36% of the total inertia and separates the predominantly
nevirapine-selected mutations A98G, K101E, V108I, Y181C,
G190A and H221Y from the other NNRTI resistance mutations.
The second principal coordinate accounts for 25% of the total
inertia and separates out V106A and F227L. The third principal
component accounts for 15% of the total inertia and separates
K103N and its associated mutations (L100I, P225H and K238T)
from G190S and Y188L. The remaining principal coordinates did
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Figure 1. Treatment associations of NNRTI-selected mutations. This ﬁgure shows the associations of 52 NNRTI-selected mutations on treatment with
efavirenz (EFV) or nevirapine (NVP), based on a Pearson’s x
2 analysis of the frequency of the mutation among sequences from individuals treated with
EFV or NVP but no other NNRTI. (a) The 16 mutations preferentially selected (P,0.05) by efavirenz; (b) the 12 mutations preferentially selected by
nevirapine; (c) the remaining 24 mutations, which were not signiﬁcantly associated with either drug.
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1480not signiﬁcantly improve the goodness of ﬁt of the multidimen-
sional scaling and were therefore not plotted. Although V179Fcov-
aried with Y181C, itisnotshown inFigure2 becauseitoccurred too
uncommonly to be accurately placed by multidimensional scaling.
NNRTI–NRTI correlations
To assess the covariation of NNRTI- and NRTI-selected
mutations, we performed a Jaccard analysis on sequences
from 9564 individuals with viruses containing at least one
mutation from each category. After adjusting for multiple com-
parisons at P,0.05, we identiﬁed 39 positive and 40 negative
statistically signiﬁcant correlations between 52 NNRTI-selected
mutations and the 17 major NRTI-selected mutations. The
strongest positive correlations were between the NRTI mutations
L74V/I and the NNRTI mutations Y181C and L100I. Another
notable, though weaker, positive correlation exists between
K65R and Y181C. The NNRTI-associated mutation A98G was
also strongly positively correlated (corrected P,0.01) with the
thymidine analogue mutations M41L, D67N, L210W and
T215F/Y. The full results of this analysis are available in Tables
S1 to S4 [available as Supplementary data at JAC Online (http://
jac.oxfordjournals.org/)].
Higher order clustering of NNRTI mutations
Approximately 17% (n¼2233) of RTsequences with one or more
NNRTI-selected mutation contained three or more NNRTI-
selected mutations. Table 2 shows the 20 most commonly
Table 1. Positively correlated pairs of NNRTI-selected mutations
Mutation X Mutation Y Covariation within EFV/NVP subsets
a
Occurrences
b Association
c
XY X only Y only P
Y181C G190A EFV 848 1711 985 1.8E-90
K101E G190A EFV, NVP 445 347 1367 3.6E-75
Y181C H221Y EFV, NVP 430 2105 264 7.2E-56
V108I H221Y EFV, NVP 255 743 430 5.4E-46
L100I K103N EFV 571 48 4910 6.7E-44
V108I Y181C NVP 424 589 2116 2.2E-32
V106A F227L NVP 96 66 128 1.7E-31
K101E Y181C EFV 351 444 2258 3.4E-28
K101E G190S EFV, NVP 133 672 194 1.6E-26
K103N P225H EFV 301 5118 30 1.2E-21
K101H G190A NVP 116 58 1766 2.4E-18
K103S G190A NVP 117 76 1753 1.2E-17
A98G Y181C EFV 319 617 2311 2.3E-14
V106I Y188L EFV 110 705 579 1.1E-11
K103N K238T NVP 219 5245 69 5.1E-11
K101H Y181C 91 84 2573 5.2E-9
A98G V108I 139 791 887 1.1E-8
G190A H221Y 174 1671 524 1.2E-8
A98G G190A 215 731 1657 3.3E-8
G190A F227L 79 1797 144 1.0E-7
V108I G190A 221 798 1606 3.4E-7
V106M V179D EFV 37 122 567 4.5E-7
K101E V108I 116 679 912 6.4E-7
Y181C G190S EFV 120 2547 224 5.8E-6
K101P K103S 24 207 175 1.5E-5
V108I F227L 46 980 175 2.1E-5
H221Y F227L 37 673 186 3.3E-5
V179F Y181C 25 1 2648 8.3E-5
K102N G190A 26 21 1868 1.8E-4
aIndicates whether the pair of mutations also covaried signiﬁcantly (uncorrected P,0.05) within the subsets of sequences from individuals
experienced in efavirenz (EFV) or nevirapine (NVP).
bOccurrences in 13039 sequences comprising the full dataset; only one isolate per patient was included in the analysis and sequences with mixtures
at a given position were excluded from comparisons at that position. XY, isolates containing both mutations; X only, isolates containing mutation X but
not mutation Y; Y only, isolates containing mutation Y but not mutation X.
cP values are uncorrected values from the Jaccard covariation analysis. All mutation pairs shown above have correlations that are signiﬁcant, with a
Holm’s correction for multiple pairwise comparisons at P,0.05.
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JACoccurring mutational triplets, of which 14 meet the deﬁnition of
a mutational cluster, or clique (each mutation covaries with each
other mutation in the triplet). The remaining six triplets contain
K103N in combination with a pair of covarying mutations. The
20 triplets listed in Table 2 occurred in 48% (n¼1069) of
sequences with three or more mutations.
In addition to the 14 mutational clusters included in the 20
most commonly occurring triplets, we identiﬁed 43 less
common clusters. The 57 clusters could be characterized as
follows: (i) 3 clusters of ﬁve mutations: A98G/K101E/V108I/
Y181C/G190A, K101E/V108I/Y181C/G190A/H221Y and K103H/
V108I/Y181C/G190A/H221Y, each of which contains within it
5 clusters of four mutations and 10 clusters of three mutations
(n¼48); (ii) 3 additional clusters of four mutations: K101H/
V108I/Y181C/G190A, K101N/K103H/Y181C/G190A and V108I/
G190A/H221Y/F227L, each of which contains 4 clusters of
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Figure 2. Multidimensional scaling of NNRTI-selected mutations. This ﬁgure is a 2-D projection of the distances among 21 of the 22 mutations
occurring in signiﬁcantly covarying pairs (corrected P,0.05, Table 1) in sequences containing at least one NNRTI-selected mutation: (a) compares
the ﬁrst and second principal coordinates; (b) compares the ﬁrst and third principal coordinates; (c) compares the second and third principal
coordinates. The distance between any two mutations is measured by their Jaccard dissimilarity coefﬁcient, JD, where JD is equal to 1 minus the
Jaccard similarity coefﬁcient. The R command cmdscale was used to compare the ﬁrst three principal coordinates from a table of JDs for each
pairwise comparison. V179F is not included in this graphic; despite a signiﬁcant positive correlation with Y181C, the comparison produces a high
Jaccard dissimilarity coefﬁcient, causing a misleading placement in multidimensional scaling.
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mutations: K101E/Y181C/G190S, K101H/Y181C/G190S, K103N/
E138Q/K238T, S105T/V106A/F227L, V106A/G190A/F227L,
V106M/G190A/F227L and V179F/Y181C/G190A. Two clusters of
four mutations and 11 clusters of three mutations were
present in more than one superset.
Discussion
Prior to the licensing of etravirine in 2008, only a few studies
examined the patterns of NNRTI resistance mutations arising fol-
lowing NNRTI treatment failure because failure with one NNRTI
generally presaged failure with a second NNRTI.
20–24 Since the
licensing of etravirine, however, several studies have examined
the likelihood of virological response to etravirine among individ-
uals in whom previous NNRTI therapies were unsuccessful.
4,25–29
Moreover, the introduction of etravirine has led to the identiﬁ-
cation of novel NNRTI-selected mutations that often decrease
susceptibility to efavirenz and nevirapine as well as to etravirine
or other second-generation NNRTIs.
2,30,31
In this study, we sought to identify and quantify associations
among NNRTI-selected mutations. Our analysis differs from pre-
vious covariation analyses
15,22in that we examined an expanded
set of mutations—including recently identiﬁed non-polymorphic
NNRTI-selected mutations
10 and the complete list of etravirine
RAMs—in a very large number of sequences. In addition, we
sought to control for associations that might reﬂect similar
treatment exposure rather than a potential biophysical mechan-
ism. Toward this end, we investigated only sequences containing
one or more NNRTI-selected mutations, to minimize the likeli-
hood that a history of NNRTI exposure (NNRTI naive versus
NNRTI experienced) was responsible for the association. We
then systematically examined the preferential selection of
NNRTI resistance mutations by efavirenz or nevirapine and the
covariation of mutations within subsets of efavirenz- or
nevirapine-experienced individuals, to assess whether pairwise
covariations could reﬂect the selection pressure of the NNRTI
received.
Although the viruses that emerge during treatment with efa-
virenz or nevirapine are often resistant to both drugs, our analy-
sis shows that efavirenz and nevirapine select for NNRTI
resistance mutations in very different proportions. For example,
nevirapine selects for V106A, Y181C/I/V and G190A signiﬁcantly
more frequently than efavirenz, whereas efavirenz preferentially
selects for L100I, K101P, V106M, Y188L, G190S and P225H.
These data suggest that patients developing virological failure
while receiving nevirapine may be at increased risk of developing
virological failure with etravirine because Y181C/I/V—which
occurs in 45% of individuals receiving nevirapine—forms the
foundation for high-level etravirine resistance.
4,12,13 Conversely,
although the two efavirenz-selected mutations L100I and
K101P are major etravirine RAMs, combined they occur in
,20% of patients receiving efavirenz. Nevirapine-associated
etravirine RAMs, including Y181C, G190A and E138A, were also
among the most commonly observed mutations in sequences
from 782 women treated with a single dose of nevirapine.
With the exception of the uncommon mutations Y181I/V,
multiple mutations are required for moderate to high-level etra-
virine resistance (.10-fold reduction in susceptibility).
4,26 We
identiﬁed 29 pairs of signiﬁcantly covarying NNRTI-selected
mutations in viruses from  13000 individuals whose sequences
contained at least one NNRTI-selected mutation. Of these
29 pairs, 22 contained at least one etravirine RAM. Nine of
these 22 pairs contained major etravirine RAMs: Y181C (n¼7),
L100I (n¼1) or K101P (n¼1), but only 2 pairs are predicted
to confer moderate to high-level etravirine resistance:
Y181C+V179F and Y181C+G190S. Although V179F and G190S
do not reduce etravirine susceptibility when they occur individu-
ally, they are highly synergistic with Y181C; Y181C+V179F
reduces etravirine susceptibility .100-fold and Y181C+G190S
reduces etravirine susceptibility  20-fold.
2,4,12,13
Approximately 17% (n¼2233) of individuals with one or more
NNRTI-selected mutations had viruses with at least three NNRTI-
selected mutations. Nearly half of these viruses contained at
least 1 of 20 common patterns of mutation triplets, suggesting
that these patterns of mutations are particularly compatible
with enzymatic function and drug resistance. Most of these pat-
terns consisted solely of mutations that covaried with one
another (mutational clusters), and the remainder consisted of
K103N in combination with one or more pairs of covarying
mutations. Y181C was the only major etravirine RAM among
the 20 most common mutational triplets. However, eight of
these triplets contained 2 of the 17 etravirine RAMs, and six tri-
plets had 3 etravirine RAMs. According to published phenotypic
data, only 1 of the 20 triplets is predicted to have high-level
resistance to etravirine—K101E, Y181C and G190S—but inter-
mediate resistance to etravirine has previously been associated
Table 2. The 20 most common mutational triplets
Mutation X Mutation Y Mutation Z Occurrences* Cluster
†
K101E Y181C G190A 242 yes
V108I Y181C G190A 190 yes
K103N Y181C G190A 180
V108I Y181C H221Y 165 yes
A98G Y181C G190A 153 yes
Y181C G190A H221Y 141 yes
K103N Y181C H221Y 135
K103N V108I H221Y 102
K101E V108I Y181C 96 yes
K101E V108I G190A 89 yes
K103N V108I Y181C 87
V108I G190A H221Y 79 yes
A98G V108I Y181C 74 yes
A98G K103N Y181C 74
A98G K101E G190A 71 yes
A98G K101E Y181C 68 yes
K101H Y181C G190A 66 yes
K101E Y181C H221Y 53 yes
A98G K103N V108I 53
K101E Y181C G190S 47 yes
*Occurrences are the number of sequences, from unique patients, that
contain mutations X, Y and Z.
†Indicates whether the triplet can be described by a mutational cluster,
where each pair of mutations within the triplet is positively correlated
with P,0.05.
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JACwith the presence of Y181C or K101E plus at least two other
NNRTI resistance mutations.
2,4,26
In a previous study, Rhee et al.
15 found 11 signiﬁcant pairwise
correlations between NNRTI-selected mutations (P,0.05 cor-
rected), of which two pairs, K103N/Y181C and K103N/V108I,
were not positively correlated in our analysis. This is almost cer-
tainly because we included only sequences containing one or
more NNRTI-selected mutation, reducing the likelihood that the
co-occurrence of mutations was confounded by a history of
NNRTI exposure. The following nine pairs were still signiﬁcantly
correlated in our analysis: Y181C/G190A, K101E/G190A, Y181C/
H221Y, V108I/H221Y, L100I/K103N, V108I/Y181C, V106A/
F227L, K101E/Y181C and K103N/P225H. Likewise, Ceccherini-
Silberstein et al.
22 reported ﬁve signiﬁcant associations among
the NNRTI-selected mutations that we studied: Y181C/H221Y,
V108I/H221Y, L100I/K103N, K103N/P225H and K103N/K238T.
Although we found that four of the pairs described by these
studies consist of mutations selected preferentially by nevirapine
(K101E, Y181C, G190A and H221Y) and that K103N and its
associated mutations are all selected preferentially by efavirenz,
we also found that the covariance of every pair was independent
of the particular NNRTI received, suggesting a potential biophysi-
cal interaction rather than treatment pressure.
In conclusion, viruses from patients with virological failure fol-
lowing nevirapine treatment are more likely to have major etra-
virine RAMs than viruses from patients who failed treatment with
efavirenz. This is because Y181C/I/V occur more commonly with
nevirapine than with efavirenz, and because mutations at this
position provide the foundation for high-level etravirine resist-
ance. Few patterns among covarying pairs of mutations and
the most common mutational triplets are predicted to be associ-
ated with moderate to high-level etravirine resistance. However,
most patterns contained one or more minor etravirine RAMs in
combination with a major etravirine RAM, particularly Y181C.
These relatively constrained higher order mutational patterns
constitute a potential target for future studies of the phenotypic
and clinical signiﬁcance of etravirine RAMs.
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